Related Experiment Video
Updated: Aug 7, 2026
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
Trastuzumab in metastatic breast cancer
F Tomao1, E Miele, G P Spinelli
1Department of Gynaecology Perinatology and Puericulture Science, University of Rome La Sapienza, Italy.
Abstract:
Metastatic breast cancer is an incurable disease in a very high percentage of patients. Despite new progress in endocrine and other systemic therapies, this evidence remains challenging for patients and clinicians. HER2 protein is a member of the epidermal growth factor family of transmembrane receptors. HER2 is overexpressed in approximately 20% to 30% of breast cancers. Overexpression of HER2 has been shown to be associated with increased tumor proliferation and relative resistance to some types of chemotherapy and hormonal therapies. Trastuzumab, a humanized monoclonal antibody directed against HER2 protein, has been shown to be an efficacious and well tolerated treatment for HER2-overexpressing metastatic breast cancer, both as a single agent and when it is used in combination with chemotherapy.
Insights
Metastatic breast cancer remains challenging, but Trastuzumab offers an effective treatment for patients with HER2-overexpressing tumors. This targeted therapy shows efficacy alone or with chemotherapy, improving outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Immunotherapy
Background:
- Metastatic breast cancer (MBC) presents significant challenges despite advances in systemic therapies.
- HER2 protein overexpression occurs in 20-30% of breast cancers, correlating with aggressive tumor behavior and treatment resistance.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Trastuzumab in treating HER2-overexpressing metastatic breast cancer.
Main Methods:
- Trastuzumab, a humanized monoclonal antibody targeting HER2, was administered.
- Treatment was assessed as a single agent and in combination with chemotherapy.
Main Results:
- Trastuzumab demonstrated significant efficacy in HER2-overexpressing metastatic breast cancer.
- The treatment was well-tolerated in patients.
Conclusions:
- Trastuzumab is an effective therapeutic option for HER2-positive metastatic breast cancer.
- Combination therapy with chemotherapy may further enhance treatment outcomes.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
